Company
Headquarters: Bresso, MI, Italy
Employees: 23
€155.0 Million
EUR as of July 1, 2024
US$166.5 Million
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $622.07 B |
Vertex Pharmaceuticals Incorporated | $121.36 B |
Regeneron Pharmaceuticals, Inc. | $115.11 B |
CSL Limited | $95.75 B |
Marinomed Biotech AG | $75.67 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease. Its product pipeline comprises Evenamide, a first add-on therapy for the treatment of patients with positive symptoms of schizophrenia; and Ralfinamide for patients with specific rare pain indications. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Newron Pharmaceuticals SpA has the following listings and related stock indices.
Stock: XETR: NP5 wb_incandescent
Stock: FSX: NP5 wb_incandescent
Stock: OTC: NWPHF wb_incandescent